Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.59
35.01
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Revenue
Sichuan Kelun Pharmaceutical Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
|
Revenue
¥22.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
11%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Revenue
¥10.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Revenue
¥10.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
22%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Revenue
¥26B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Revenue
¥39.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Revenue
¥561.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sichuan Kelun Pharmaceutical Co Ltd
Glance View
Sichuan Kelun Pharmaceutical Co., Ltd., established in 1997 and headquartered in Chengdu, China, has rapidly emerged as a formidable player in the pharmaceutical industry. The company specializes in the research, development, and production of a diverse range of pharmaceuticals, including innovative drugs, generic medications, and active pharmaceutical ingredients (APIs). Kelun has built a strong reputation for its commitment to quality and safety, evidenced by its compliance with international regulatory standards and certifications such as FDA and EMA approvals. With a robust portfolio that spans key therapeutic areas like oncology, cardiovascular diseases, and infectious diseases, Kelun not only caters to the growing domestic demand but is also expanding its footprint in the global market, making it an appealing prospect for investors seeking growth in the health sector. As the pharmaceutical landscape in China evolves, fueled by increasing healthcare expenditures and an aging population, Kelun is strategically positioned to capitalize on these trends. The company's significant investments in research and development underscore its ambition to innovate and introduce new therapies that meet pressing healthcare needs. Furthermore, strategic collaborations with international partners enhance its technological capabilities and market reach. With strong financial metrics that reflect steady revenue growth and profitability, Kelun stands poised to leverage its operational expertise and strategic initiatives for sustained expansion. For investors, Sichuan Kelun Pharmaceutical represents an attractive opportunity to tap into the burgeoning pharmaceutical market led by a company marked by quality, innovation, and a clear vision for future growth.
See Also
What is Sichuan Kelun Pharmaceutical Co Ltd's Revenue?
Revenue
22.5B
CNY
Based on the financial report for Sep 30, 2024, Sichuan Kelun Pharmaceutical Co Ltd's Revenue amounts to 22.5B CNY.
What is Sichuan Kelun Pharmaceutical Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
11%
Over the last year, the Revenue growth was 8%. The average annual Revenue growth rates for Sichuan Kelun Pharmaceutical Co Ltd have been 9% over the past three years , 6% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
